GSK: priority review for a new antibiotic in US

(CercleFinance.com) - The US health authorities have granted a priority review procedure to gepotidacin, a new antibiotic developed by GSK to treat cystitis in adolescents and women, the pharmaceutical group announced on Wednesday.


The laboratory reports that the FDA has agreed to review the marketing application for this oral antibiotic intended for the treatment of uncomplicated urinary tract infections in women weighing over 40kg and adolescent girls over 40kg and over 12 years of age.

This review period is expected to last six months, with a final decision expected in March 2025.

GSK argues that the need for new treatments is due to the emergence of more resistant bacterial strains causing infections, often resulting in failure of traditional therapies.


Copyright (c) 2024 CercleFinance.com. All rights reserved.